Regeneron announces additional data from aflibercept Phase 3 trial on colorectal cancer

Download PDF Copy

Reviewed

Regeneron Pharmaceuticals, Inc.Sep 26 2011

Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that additional data from the Phase 3 VELOUR trial will be presented at the 2011 European Multidisciplinary Cancer Congress (EMCC) which will take place from September 23-27 in Stockholm, Sweden.

The data will be presented as a late breaker, by Prof. Josep Tabernero, on Sunday, September 25, at 6:40 AM EDT. Prof. Tabernero is Head of Medical Oncology at Vall d'Hebron University Hospital, Spain, and one of the lead investigators in the VELOUR trial. The title of his presentation is "Results from VELOUR, a Phase 3 Study of Aflibercept Versus Placebo in Combination with FOLFIRI for the Treatment of Patients with Previously Treated Metastatic Colorectal Cancer: Results from Prespecified Subgroup Analyses."

Source:

Regeneron Pharmaceuticals, Inc.

Posted in: Drug Trial News | Medical Condition News

Comments (0)

Download PDF Copy

Suggested Reading

Loneliness and isolation associated with higher death risk in cancer patients

Blocking two enzymes weakens prostate tumors and boosts drug effectiveness

Bridging innovation and equity to end cervical cancer worldwide

Predictive models identify high-risk liver cancer recurrence

New personalized therapy boosts tamoxifen effectiveness in breast cancer patients

Fatty acids found to be a primary driver of triple-negative tumor growth

WashU startup Prognosia acquired by Lunit to advance AI-based breast cancer prediction

New imaging technique boosts survival in prostate cancer patients

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

(Logout)

Post

Sign in to keep reading

We're committed to providing free access to quality science. By registering and providing insight into your preferences you're joining a community of over 1m science interested individuals and help us to provide you with insightful content whilst keeping our service free.